Review Article

The Evolution of Antimycobacterial Agents from Non-Antibiotics

Mark Wainwright[1,], Leonard Amaral[2], Jette E. Kristiansen[3]*

[1] School of Pharmacy & Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF United Kingdom
[2] Unit of Mycobacteriology, Institute of Hygiene and Tropical Medicine, Universidade Nova de Lisboa, Lisbon, Portugal
[3] MEMPHYS Center for Biomembrane Physics, Department of Physics and Chemistry, Southern Danish University, Campusvej 55, DK-5230 Odense M, Denmark

Corresponding Author & Address:

Mark Wainwright[*]

School of Pharmacy & Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF United Kingdom;   Email: mark_wainwright@hotmail.com

ABSTRACT

The antimicrobial action of a number of non-antibiotic drugs has been demonstrated in recent years, for example the antimycobacterial activity associated with the phenothiazine neuroleptic class. However, as with other classes of non-antibiotics, such activity may be traced back to common precursor structures such as the phenothiazinium dye, methylene blue. While the rising tide of antimicrobial drug resistance has nullified the effects of many conventional agents, several of the original lead compounds and their non-antibiotic derivatives may have a new part to play in the chemotherapy of infectious disease, particularly in the management of tuberculosis.

INTRODUCTION

Among therapeutic approaches, antimicrobial chemotherapy has a relatively short history – around 120 years at the outside, but perhaps more acceptably 75 years since the beginning of clinical sulphonamide use – and derives from much simpler principles. While the use of antibacterials – natural product antibiotics or synthetic-/semi-synthetic agents – is widespread, the huge strides made against infection in the 1940s and 50s are no longer possible, mainly due to the widespread evolution of drug resistance mechanisms among bacteria, in some cases conferring resistance to all known clinical agents. A *prima facie* example of this phenomenon is that of *Mycobacterium tuberculosis*, the principal causative agent in pulmonary tuberculosis that has evolved from multi-drug resistant (MDR, resistance to isoniazid

(INH) and rifampicin (Rif)) to extensively drug resistant (XDR, resistance to INH, Rif, streptomycin, any fluoroquinolone and any of the injectable anti-tuberculosis drugs amikacin, kanamycin and capreomycin) and more recently to total drug resistance (TDR) [1]. In each case, whether MDR/XDR/TDR TB is due to over- or mis-use of the available agents, or required prolonged therapy involving periods of many months - or even an excess of one year as is the situation for therapy of a new case of tuberculosis - or simply because of therapeutic longevity, sufficient selective pressure has been brought to bear, and alternative drugs are in very short supply indeed. This situation is not helped by the single mode-of-action antibacterial approach utilised in the majority of cases. This provides effective selective pressure, it being relatively simple to nullify such drugs in the laboratory via single-point mutation to one member of a drug class, and this may be readily followed by resistance to two or more drugs [2]. Inducement of multi-drug resistance may involve resistance to structurally-similar drugs due to the mutated target [3], or to drugs that are not structurally related [4]. Clearly there is an argument here for the introduction of less-targeted

therapeutics, at least in terms of microbial anatomy. These are currently rare in practice, and multi-site attack relies on therapeutic co-administration. Nor is the parlous state of our antimicrobials the sole concern. Damage to the internal flora following a period of oral administration is often also a cause of illness, and is particularly problematic in the elderly due to the survival and overgrowth of refractory organisms, such as the Gram-positive anaerobe *Clostridium difficile* or the yeast *Candida albicans* [5].

The term *chemotherapy* was coined by the German scientist Paul Ehrlich, relatively late in his highly productive life. Ehrlich's ideas on differential cell staining by aniline dyes during the late 19th and early 20th centuries laid the foundations for what became known as selective toxicity, a principle which still underpins our modern use of antimicrobial drugs. However, Ehrlich's principal contribution to drug discovery was to realise that there was a relationship between dye chemical structure and cell, or organelle, specificity. This quantum leap was manifest in his involvement in the successful clinical treatment of malaria, reported in 1891 [6, 7], for which Ehrlich used the phenothiazinium dye methylene blue (Fig. 1).


Fig. 1. Drug evolution from methylene blue (phenothiazinium class). Key to significant alterations: C = chromophore change; SC = side chain variation.

The phenothiazine neuroleptics were developed as a result of clinical observations

arising from the use of methylene blue in psychosis as early as 1899 [8-10]. A series of phenothiazines

were then synthesised and tested, those with the alkylaminoalkylamino- side chain (including the ring nitrogen) often exhibiting activity, usually either as H_1 or D_2 antagonists, depending on the length of the side chain, e.g. promethazine and chlorpromazine respectively. Chlorpromazine (CPZ, Fig. 1) became a widely used major tranquiliser for use in the treatment of schizophrenia, and improved derivatives, such as thioridazine (Fig. 1) have been synthesised. In addition, bioisosteric replacement of *N*-10 in the phenothiazine chromophore with trigonal carbon furnished the thioxanthenes, such as flupenthixol, and the alkylaminoalkylamino– side chain can still be seen in more modern D_2/5-HT-active agents such as clozapine and olanzapine (Fig. 2). Similarly, analogue synthesis based on the phenothiazines led to the development of the tricyclic antidepressant class, including imipramine and amitriptyline (Fig. 2).

Fig. 2. The alkylaminoalkylamino-type side chain shown in Paludenblau, and emphasised in subsequent neuroleptic molecules (* denotes important stereochemical centre).

The combination of a basic side chain and a tricyclic – normally heterocyclic – chromophore may be observed in each of these therapeutics. In simplistic chemical terms, they represent the same general type of molecule as the early, functionalised methylene blue derivatives

synthesised by Mietzsch and Mauss at Bayer [10] as potential antimicrobial agents (c.f. Paludenblau and modern CNS agents, Fig. 2). While obviously these chemists were not working to a molecular targeting paradigm, as would be expected in modern pharmaceutical research, the compound screening protocols normally included small animals. Thus, organ sequestration/simple pharmacokinetic and toxicity studies would have been possible, in turn allowing a reasonable attempt at the development of rational structure-activity relationships.

Methylene blue is a highly hydrophilic dye. This is reflected in its short half-life in mammalian systems, the greater proportion of the compound appearing rapidly in the urine. What is less well appreciated is the reduction-oxidation ('redox') behaviour of the dye on interaction with the metabolism. Reduced, or 'leuco' methylene blue no longer carries a delocalised positive charge, and exists, at physiological pH, as a neutral molecule. This alters its behaviour in terms of compartmentalisation, serum binding etc. It has also been proposed that the uptake of methylene blue by microbes involves this reduction stage, which facilitates its passage to the cell interior where it may be re-oxidised in the cytoplasm. De Witt in 1913 [11] reported such phenomena in the early years of the last century, having tested methylene blue in a small animal tuberculosis model: grey-coloured tubercles in the post-mortem lung turned blue on exposure to the air.

CNS AGENTS

The early phenothiazine neuroleptic drugs were developed rather empirically – not surprising, given the scant contemporary knowledge of receptor function. The removal of violent symptoms in schizophrenic patients, sufficient for their daily management, was a most persuasive argument for the clinical acceptance of chemical administration. However, the subsequent appearance of serious side-effects was an obvious indicator of a lack of correct selectivity [12, 13].

The development of both the drug chromophore and side chain to this end obviously produced a considerable number of active compounds, covering a wide structural range. As mentioned, the spin-off development of the tricyclic antidepressants may be included here [14]. The whole collection thus represents a significant

number of clinically-acceptable examples of the tricyclic chromophore / basic side chain molecular type.

Although the antimalarial [6, 7, 15, 16] and antibacterial properties of CPZ have been known for decades, due to its frequent serious side effects, it has never been seriously considered for therapy of bacterial infections [17- 22]. However, with the advent of MDR TB infections in the 1980s in areas where TB was thought to have been reduced to the point of eradication, the search for effective anti-MDR TB compounds was begun. Among the compounds examined was Largactil [23, 24], then the commercial preparation of CPZ, which had been shown in the 1950s to cure TB infections and later to have *in vitro* activity against all forms of antibiotic-resistant strains of *M. tuberculosis* [25, 26]. However, the *in vitro* activities occurred at concentrations which were beyond those clinically achievable in serum, but CPZ and other phenothiazines have very high affinity for the lungs, ≤ 100 μg/g wet tissue [27, 28]. At this concentration Kristiansen and Vergmann [26] found that all mycobacteria, independent of resistance pattern, were inhibited by ≤ 25 μg/ml of CPZ on agar. Although this concentration is hundreds of times greater than that safely possible in the human, phenothiazines are known to be concentrated by up to 300% in the tissues, allowing the possibility that the antibacterial concentration might be reached *in vivo*.

These results were confirmed in 1992 and it was also demonstrated that CPZ kills *M. tuberculosis* in newly-phagocytosed human macrophages [29, 30], but interest in CPZ remained low - the CNS side-effects of the agent prevented any serious consideration of its use as an anti-TB drug. Nevertheless, since thioridazine (TZ), the neuroleptic that replaced CPZ, is a much milder drug producing fewer serious side effects than CPZ and was the *in vitro* equal of CPZ with respect to its activity against all forms of antibiotic-resistant strains of *M. tuberculosis* [29], interest in TZ as an anti-MDR TB drug gained credence and it was soon shown to promote the killing of multi-drug resistant strains of *M. tuberculosis* by non-killing macrophages at concentrations in the experimental medium that were below those used in the initial therapy of psychosis [30]. TZ has now been shown to cure both antibiotic-susceptible and MDR TB infection in a murine model [31, 32], and ten out of

twelve cases of XDR TB patients [33]. Protocols have now been published for the therapy of XDR TB whose prognosis is solemn, and may be conducted on a compassionate basis [34].

The widespread use of chlorpromazine during the 1950s also yielded anecdotal observations that the phenothiazine acted synergistically with anticancer therapy [35]. This synergism was later shown to result from the inhibition of the eukaryotic transporter P-glycoprotein (Pgp1) which when over-expressed renders the cancer cell susceptible to the anticancer agent to which it was originally resistant [36]. Similarly, the demonstration that chlorpromazine reduces sensitive and resistant bacteria strains to antibiotics [37, 38] was later interpreted to result from an inhibition of an efflux pump system that extruded the antibiotic prior to its reaching its intended target [39]. Since these studies, phenothiazines have been shown to inhibit the *NorA* efflux pump of *Staphylococcus aureus* [40], the *QAC* efflux pump of the plasmid carried by a *Staphylococcus aureus* multi-drug resistant strain [41], the efflux pump system of E. coli [42], the *AcrAB* efflux pump of E. coli [43, 44], the main efflux pump of Mycobacterium smegmatis [45] and the efflux pump of *Mycobacterium avium* [46]. The phenothiazines chlorpromazine [47] and thioridazine [48] have been shown to affect the activity of genes that regulate and code for the *AcrAB* efflux pump of E. coli as well as that of *Salmonella enteric* serovar Enteritidis [49]. That the activity of thioridazine on bacterial genes is probably universal is illustrated by its effects on the main survival genes of *Mycobacterium tuberculosis* [50].

The mechanism by which this phenothiazine directly affects the activity of an efflux pump has been extensively studied. The effects are indirect and result from the inhibition of calcium binding to calcium-dependent enzymes involved in metabolism [51]. This inhibition reduces the formation of hydronium (H_3O^+) ions that result from metabolism needed for the activity of the pump [52]. Because the dissociation of the substrate from the transporter is pH-dependent – high dissociation constant in low pH and low dissociation constant in high pH [53] - the internal pH of the transporter is not reduced to a level required for dissociation of the substrate as a consequence of reduced availability of hydronium ions [52, 54].

Although nothing has essentially been reported with respect to structural activity relationship (SAR) for thioridazine derivatives that are effective against *Mycobacterium tuberculosis*, a recent study focused on synthesized quaternized chlorpromazine, triflupromazine, and promethazine derivatives, demonstrated that these derivatives had antitubercular activities against both actively growing and non-replicating references wild-type *Mycobacterium tuberculosis* H37Rv [55]. All active compounds were found to have no toxicity against a Vero cell line. Importantly, whereas N-Allylchlorpromazinium bromide rendered the derivatives less active, the replacement of the allyl with benzyl or substituted benzyl promoted significant greater anti-tubercular activity. Moreover, the substitutents that had powerful electron withdrawing properties were essential for the improved activity of the derivatives. All derivatives that contained branching at the carbon chain expressed significantly weaker activity. The main conclusion that can be drawn from these studies is that structures that possessed N-(4- or 3-chlorobenzyl) substitution expressed the highest anti-tubercular activity.

Phenothiazines appear to have other antibacterial effects, causing the elimination of plasmids from Gram-negative [56, 57] and Gram-positive bacteria [58, 59]. Phenothiazines promote the elimination of plasmids from bacteria (plasmid curing) due to the smaller concentration (MIC) of the agent needed to inhibit plasmid replication as opposed to those required for the inhibition of replication of the bacterium. This inhibition results from the intercalation of the agent between nucleic bases of DNA, especially at regions rich in guanosine and cytosine [60]. However, because phenothiazines have significant effects on the cell envelope of bacteria [61, 62] the more facilitated elimination of smaller plasmids as opposed to larger plasmids may be, at least partially due to the size of the plasmid itself [63]. Because the antibiotic resistance of bacterial pathogens relevant to human and animal husbandry is often due to plasmids carrying antibiotic resistance genes [64], the elimination of plasmids from bacteria provides a way to eliminate clinical antibiotic resistance in infection-causing bacteria.

Interestingly, because industry has been told that processes employing bacteria must be conducted with bacteria that have no antibiotic resistance, elimination of plasmids is now being pursued vigorously [65].

During recent years pre-administration of phenothiazines to animals has provided protection from virulent *Salmonella* infections [66, 67]. Because protection takes place with *in vivo* concentrations of the phenothiazine which are 30 times lower than those needed to inhibit the *in vitro* replication of the organism, the mechanism by which protection is afforded is not dependent upon the effects of the agent noted *in vitro*. If the *in vivo* concentration of the agent is so low, how does it protect from an infection by a highly virulent *Salmonella* strain? Moreover, because the mode of infection involved IP administration and subsequent rapid phagocytosis of the bacteria by neutrophils does not result in the killing of the organism, how does the agent protect from infection? The answer may lie in the following: within minutes of phagocytosis and fusion of the lysosome with the phagosome, the low pH of this vacuole induces the activation of two two-component regulons; *PmrA/B* and *PhoP/Q*. The activation of these regulons results in the rapid synthesis of Lipid A which is introduced into the nascent lipopolysaccharide layer of the outer cell wall. Once this occurs the organism is resistant not only to the hydrolytic enzymes of the phagosome-lysosome vacuole, but also to practically everything else [68]. It is postulated that because pre-administration of the phenothiazine results in the accumulation of the agent by lysosome-rich macrophages such as the neutrophil [69, 70], the concentration of the phenothiazine within the lysosome may be sufficiently high to inhibit the first step of the two component regulon-namely, the sensor function of the *PmrA* receptor present on the surface of *Salmonella*. Support for this possibility is provided by the non-specific binding of the phenothiazine chlorpromazine to the surface of the cell blocking access of an O antibody to the O antigen surface of the bacterium [64]. Nevertheless, other possibilities that contribute to the protection provided by the phenothiazine exist in as much as the phenothiazine chlorpromazine has been shown to modulate secretion and syntheses of cytokines involved in protection from infection [71].

THE LIPOPHILIC CHROMOPHORE/BASIC SIDE-CHAIN PARADIGM

In Denmark membrane stabilisers such as anaesthetics, the phenothiazines and chloroquine have been studied in respect to efflux inhibition [72-74]. Kristiansen *et al.* [73-77] have investigated the inhibition of potassium efflux and antimicrobial, immunostimulation and reversal of resistance potency in the same compounds. Interestingly, the observed antimicrobial activities of different phenothiazine and thioxanthene analogues and their metabolites [76-79] are independent of their CNS activity as seen, for example, in the antihistaminic and neuroleptic phenothiazines [24, 80, 81].

It can be emphasized that phenothiazine analogues with an exocyclic double bond (the thioxanthenes) are more potent antimicrobials *in vitro* than the corresponding compounds lacking it [24, 76, 81, 82]. The (Z) isomeric thioxanthenes (Fig. 2) generally exhibit stronger neuroleptic activities compared to the (E) isomers. The possibility therefore exists to separate the CNS and antimicrobial activities by choosing the latter compounds as antimicrobials and increasing this activity by optimising ring substitution using e.g. halogens [74, 76, 77].

Similar behaviour is exhibited by classical phenothiazine compounds exhibiting (+/-) stereochemistry, e.g. promethazine, alimemazine, mepromazine and thioridazine [76, 77, 83, 84]. (+/-) Thioridazine (Fig. 2) is especially important, because this mixture exhibits very potent antimicrobial activity against both resistant (MDR, XDR) and sensitive mycobacterial strains. These compounds are also very active as efflux inhibitors in the reversal of antimicrobial resistance. Unexpectedly, (-)-thioridazine, without CNS activity, is the most potent [77, 83, 84]. This observation constitutes a medical breakthrough for the use of phenothiazines and their analogues, as well as their more active metabolites, together with classical chemotherapeutics for synergy and/or for reversal of resistance *in vivo* [75, 79]. Amaral *et al.* have shown that it is possible to use thioridazine as a "helper compound" in MDR and XMDR TB in *in vitro*, *ex vivo* and *in vivo* investigations [33].

Similarly, Abbate *et al.* have reported successful treatment of seriously ill patients with XDR TB with low doses of thioridazine as a helper compound in a regime together with anti-TB compounds against which the TB strains are resistant [85]. Ehrlich had noted such possibilities in neurotropic compounds, in relation to his theories for developing chemotherapeutics from dye series to be used in serious intracellular infectious disease [75, 86]. Now, a century after Ehrlich, a phenothiazine derivative synthesized in the late 1950s has a role to play in one of the most serious bacterial threats to mankind, XDR TB. The phenothiazines may now have a renaissance as a new antimicrobial class.

The phenothiazines, thioxanthenes and dibenzazepine antidepressants, all obey the lipophilic chromophore/basic side chain paradigm. These lipophilic chemicals and their stereochemical variations have been investigated since late in the 1970s . However, so far there has been much less investigation of the modern antidepressant (SSRI) drugs as efflux inhibitors [37, 87-92] than of the phenothiazines and other, older psychopharmacological agents.

It is perhaps ironic, then, that these less related CNS agents, such as the selective serotonin reuptake inhibitors femoxitine, paroxetine, fluoxetine, sertraline and cipramil and their stereochemical analogues have now been shown to act also as antibacterial, antifungal, antiviral and antiprotozoal compounds both *in vitro* and *in vivo* and as efflux pump inhibitors, exhibiting particular activity against different Gram-positive and Gram-negative bacteria [88-92]. However, on structural consideration, each of these SSRIs can be seen to fulfil the same chromophore/side chain requirement (Fig. 3), and so might also be used as helper compounds in the future as demonstrated by Cecchelli *et al.* in 2010 in the treatment of HIV infected persons [93].


Fig. 3. Imipramine and exemplar SSRI molecules. Chromophore or chromophore-equivalent shown in grey, side-chain/side-chain equivalent in black.

FUTURE CONSIDERATIONS

Because of the urgency required for the therapy of an essentially lethal infection, this review primarily focused on the potential that the phenothiazine thioridazine has for successful therapy MDR/XDR and TDR MT infections. That this potential is real, witness the recently published study that demonstrated again that the use of thioridazine cures the XDR TB [94]. However, it should be noted that in all probability, thioridazine will be useful for the therapy of any intracellular infection such recurrent *Staphylococcal* pulmonary and bone marrow infections [95], as well as Chagas disease, leishmania, and even malaria, given that its precursor phenothiazine chlorpromazine has already been shown to kill the infectious agent *in situ* [96-100].

CONCLUSION

The chemical links demonstrated here between early dyes and modern drugs are

becoming better appreciated by those involved in the pharmaceutical field. In many cases, these should be obvious, given the gross structural similarities in cases such as methylene blue and the phenothiazine CNS agents, but without knowledge of the chemical genealogy involved, they may be less apparent in second- and third-generation agents, such as the SSRIs. In addition, the chemical links do not explain entirely the antimicrobial activities of the non-antibiotic derivatives, although, as noted above, the *in vivo* reduction of methylene blue and its incorporation as the neutral leucobase by tubercles hints at the similarity.

In terms of therapeutic utility, the improvement in selectivity and action of neuroleptic drugs progressing from chlorpromazine to thioridazine and the thioxanthenes allowed effective therapy at lower doses with fewer side effects. A similar pattern has been shown with the antidepressants, from tricyclics to SSRIs. The discovery that many of these agents are also antimicrobial thus offers the prospect particularly of new approaches – and templates for novel drug design - in antibacterial chemotherapy. Given the modern climate of drug-resistant bacteria, this is of considerable importance, and even more so in the area of drug-resistant tuberculosis. The adjunctive use of suitable CNS agents alongside conventional antibacterial agents in order to circumvent clinical resistance is likely to be similarly effective.

Finally, but of no less import, the discovery of antimicrobial effects in drugs/compounds which are already known and in some cases have been in clinical use for many years should provide chemotherapy at much lower cost, thus being of considerable potential in aiding less fortunate health economies.

COMPETING INTERESTS

None to declare.

REFERENCES

[1]   Gillespie SH, Singh K. XDR-TB, What is it; How is it treated; and why is therapeutic failure so high? *Recent Pat Antinfective Drug Discov.* **2011;** 6: 77-83.

[2]   Viveiros M, Jesus A, Brito M, Leandro C, Martins M, Ordway D, Molnar AM, Molnar J, Amaral L. Inducement and reversal of tetracycline resistance in Escherichia coli K-12 and expression of proton gradient-dependent multidrug efflux pump genes. *Antimicrob Agents Chemother.* **2005;** 49; 3578-82.

[3]   Barbier F, Wolff M. Multi-drug resistant Pseudomonas aeruginosa: towards a therapeutic dead end? *Med Sci (Paris).* **2010;** 26: 960-8.

[4]   Pagès JM, Amaral L. Mechanisms of drug efflux and strategies to combat them:challenging the efflux pump of Gram-negative bacteria. *Biochim Biophys Acta.* **2009;** 1794: 826-33.

[5]   Woodmansey EJ, McMurdo ME, Macfarlane GT, Macfarlane S. Comparison of compositions and metabolic activities of fecal microbiotas in young adults and in antibiotic-treated and non-antibiotic-treated elderly subjects. *Appl Environ Microbiol.* **2004;** 70: 6113-22.

[6]   Guttmann P, Ehrlich P. Ueber die wirkung des methylenblau bei malaria. *Berlin Klinische Wochschrift.* **1891;** 39: 953-6.

[7]   Oholow MJ, Moosmann B. Foundation review: Phenothiazines: The seven lives of pharmacology's first lead structure. *Drug Discov Today.* **2011;** 16: 119-31.

[8]   Bodoni M. Dellàzione sedative delblue di metilene in vaire forme di psicosi. *Clinica Medica Italiana.* **1899;** 24: 217-22.

[9]   Kristiansen JE. Dyes, antipsychotic drugs and antimicrobial activity. Fragments of a development with special reference to the influence of Paul Ehrlich. *Dan Med Bull.* **1989;** 36:178-85.

[10]   Schulemann W. Synthetic anti-malarial preparations. *Proc R Soc Med.* **1932;** 25: 897-905.

[11]   DeWitt LM. Preliminary report of experiments in the vital staining of tubercles. *J Infect Dis.* **1913;** 12: 68-92.

[12]   Mitchell SC. The toxicity of phenothiazines. *Drug Metabol Drug Interactions.* **1994;** 11: 201-36.

[13]   Amaral L, Kristiansen JE, Viveiros M, Atouguia J. Activity of phenothiazines against antibiotic-resistant *Mycobacterium tuberculosis*: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. *J Antimicrob Chemother.* **2001;** 47: 505-11.

[14]   López-Muñoz F, Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. *Curr Pharm Des.* **2009;** 15: 1563-86.

[15]   Oz M, Lorke DE, Petroianu GA. Methylene blue and Alzheimer's disease. *Biochem Pharmacol.* **2009;** 78: 927-32.

[16]   Kristiansen JE, Jepsen S. The susceptibility of Plasmodium falciparum *in vitro* to chlorpromazine and the stereo-isomeric compounds cis(Z)- and trans(E)-clopenthixol. *Acta Pathol Microbiol Immunol Scand B.* **1985;** 93: 249-51.

[17]   Bourdon JL. Contribution a l'etude des propriétés antibiotiques de la chlorpromazine ou 4560 RP. *Ann Inst Pasteur.* **1961;** 101: 876-86.

[18]   Chattopadhyay D, Das SK, Patra AR, Bhattacharya SK. Non-antibiotics – an alternative for microbial resistance: scope and hope. In: Ahmad I & Aqil F, ed. *New strategies Combating Bacterial Infection Weinhein*,

Wiley-VCH Verlag GmbH & Co. KGaA. **2008;** 89-126.

[19] Kristiansen JE. Antimicrobial activity of non-antibiotics. *APMIS Supplement.* **1992;** 30: 7-14.

[20] Wainwright M, Amaral L. The phenothiazinium chromophore and the evolution of antimalarial drugs. *Trop Med Int Health.* **2005;** 10: 501-11.

[21] Amaral L, Viveiros M, Kristiansen JE. Phenothiazines: potential alternatives for the management of antibiotic resistant infections of tuberculosis and malaria in developing countries. *Trop Med Int Health.* **2001;** 6: 1016-22.

[22] Kristiansen JE, Amaral L. The potential management of resistant infections with non-antibiotics. *J Antimicrob Chemother.* **1997;** 40: 319-27.

[23] Popper M, Lorian V. Làction de la chlorpromazine sur les microbes et le copmplexe bacterériostatique "*in vitro*". *La Press Médicale.* **1959;** 67: 212-3.

[24] Rajsner M, Metysová J, Svátek E *et al.* 2-and 3-Fluoro derivates of clorotepin and related compounds: 6-and 7-fluroderivative of chlorprothixene. *Collection of Czechoslovak Chemical Communications.* **1975;** 40: 719-37.

[25] Molnár J, Béladi I, Földes I. Studies on antituberculotic action of some phenothiazine derivatives *in vitro*. Zentralblatt für Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. 1. *Abteilung. Originale. Reihe A.* **1977;** 239: 521-6.

[26] Kristiansen JE, Vergmann B. The antibacterial effect of selected phenothiazines and thioxanthenes on slow-growing mycobacteria. *Acta Pathol Microbiol Immunol Scand B.* **1986;** 94: 393-8.

[27] Forrest FM, Forrest IS, Roizin L. Clinical, biochemical and post mortem studies on a patient treated with chlorpromazine. *Revue Agressologie.* **1963;** 4: 259-64.

[28] Gruenke LD, Craig JC, Klein FD, Nguyen TL, Hitzemann BA, Holaday JW, Loh HH, Braff L, Fischer A, Glick ID, et al. Determination of chlorpromazine and its major metabolites by GC/MS: application to biological fluids. *Biomed Mass Spectrom.* **1985;** 12: 707-13.

[29] Amaral L, Kristiansen JE, Abebe LS, Millett W. Inhibition of the respiration of multi-drug resistant clinical isolates of *Mycobacterium tuberculosis* by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. *J Antimicrob Chemother.* **1996;** 38: 1049-53.

[30] Ordway D, Viveiros M, Leandro C, Bettencourt R, Almeida J, Martins M, Kristiansen JE, Molnar J, Amaral L. Clinical concentrations of thioridazine kill intracellular multidrug-resistant *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother.* **2003;** 47: 917-22.

[31] Martins M, Viveiros M, Kristiansen JE, Molnar J, Amaral L. The curative activity of thioridazine on mice infected with *Mycobacterium tuberculosis*. *In Vivo.* **2007;** 21: 771-5.

[32] van Soolingen D, Hernandez-Pando R, Orozco H, Aguilar D, Magis-Escurra C, Amaral L, van Ingen J, Boeree MJ. The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. *PLoS One.* **2010;** 5(9) pii: e12640.

[33] Amaral L, Boeree MJ, Gillespie SH, Udwadia ZF, van Soolingen D. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! *Int J Antimicrob Agents.* **2010;** 35: 524-6.

[34] Amaral L, Viveiros M, Molnar J & Kristiansen JE.

Effective therapy with the neuroleptic thioridazine as an adjunct to second line of defence drugs, and the potential that thioridazine offers for new patents that cover a variety of "new uses". *Recent Pat Antinfective Drug Discov.* **2011;** 6: 84-7.

[35] Jones GR. Cancer therapy: phenothiazines in an unexpected role. *Tumori.* **1985;** 71: 563-9.

[36] Molnár J, Szabo D, Mándi Y, Mucsi I, Fischer J, Varga A, König S, Motohashi N. Multidrug resistance reversal in mouse lymphoma cells by heterocyclic compounds. *Anticancer Res.* **1998;** 18: 3033-8.

[37] Kristiansen JE. Antimicrobial activity of non-antibiotics. *ASM News.* **1991;** 57: 135-9.

[38] Amaral L, Kristiansen J, Lorian V. Synergic effect of chlorpromazine on the activity of some antibiotics. *J Antimicrob Chemother.* **1992;** 30: 556-8.

[39] Kristiansen MM, Leandro C, Ordway D, Martins M, Viveiros M, Pacheco T, Kristiansen JE, Amaral L. Phenothiazines alter resistance of methicillin-resistant strains of *Staphylococcus aureus* (MRSA) to oxacillin *in vitro*. *Int J Antimicrob Agents.* **2003;** 22: 250-3.

[40] Kaatz GW, Moudgal VV, Seo SM, Kristiansen JE. Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in *Staphylococcus aureus*. *Antimicrob Agents Chemother.* **2003;** 47 : 719-26.

[41] Costa SS, Ntokou E, Martins A, Pournaras S, Couto I, Amaral L. Identification of the plasmid-encoded qacA efflux pump gene in meticillin-resistant *Staphylococcus aureus* (MRSA) strain HPV107, a representative of the MRSA Iberian clone. *Int J Antimicrob Agents.* **2010;** 36: 557-61.

[42] Molnár J, Hevér A, Fakla I, Fischer J, Ocsovski I, Aszalos A. Inhibition of the transport function of membrane proteins by some substituted phenothiazines in E. coli and multidrug resistant tumor cells. *Anticancer Res.* **1997;** 17: 481-6.

[43] Viveiros M, Jesus A, Brito M, Leandro C, Martins M, Ordway D, Molnar AM, Molnar J, Amaral L. Inducement and reversal of tetracycline resistance in Escherichia coli K-12 and expression of proton gradient-dependent multidrug efflux pump genes. *Antimicrob Agents Chemother.* **2005;** 49: 3578-82.

[44] Viveiros M, Dupont M, Rodrigues L, Couto I, Davin-Regli A, Martins M, Pagès JM, Amaral L. Antibiotic stress, genetic response and altered permeability of E. coli. *PLoS One.* **2007;** 2: e365.

[45] Rodrigues L, Aínsa JA, Amaral L, Viveiros M. Inhibition of drug efflux in Mycobacteria with phenothiazines and other putative efflux inhibitors. *Recent Pat Antiinfective Drug Discov.* **2011;** 6: 118-127.

[46] Rodrigues L, Sampaio D, Couto I, Machado D, Kern WV, Amaral L, Viveiros M. The role of efflux pumps in macrolide resistance in *Mycobacterium avium* complex. *Int J Antimicrob Agents.* **2009;** 34: 529-33.

[47] Bailey AM, Paulsen IT, Piddock LJ. RamA confers multidrug resistance in *Salmonella enterica* via increased expression of acrB, which is inhibited by chlorpromazine. *Antimicrob Agents Chemother.* **2008;** 52: 3604-11.

[48] Amaral L, Fanning S, Spengler G *et al.* Genetic regulation, physiology, assessment and inhibition of efflux pumps responsible for multi-drug resistant phenotypes of bacterial pathogens. In Bonilla AR, Muniz KP, eds. *Antibiotic Resistance: Causes and Risk Factors,*

Mechanisms and Alternatives. New York, Nova Science Publishers Inc., **2009;** 313-32.

[49] Spengler G, Rodrigues L, Martins A, Martins M, McCusker M, Cerca P, Machado L, Costa SS, Ntokou E, Couto I, Viveiros M, Fanning S, Molnar J, Amaral L. Genetic response of *Salmonella enterica* serotype Enteritidis to thioridazine rendering the organism resistant to the agent. *Int J Antimicrob Agents.* **2012;** 39: 16-21.

[50] Dutta NK, Mazumdar K, Dastidar SG, Karakousis PC, Amaral L. New patentable use of an old neuroleptic compound thioridazine to combat against tuberculosis: gene regulation perspective. *Recent Pat Anti-infective Drug Discov.* **2011;** 6: 128-38.

[51] Martins A, Machado L, Costa S, Cerca P, Spengler G, Viveiros M, Amaral L. Role of calcium in the efflux system of Escherichia coli. *Int J Antimicrob Agents.* **2011;** 37: 410-4.

[52] Amaral L, Cerca P, Spengler G, Machado L, Martins A, Couto I, Viveiros M, Fanning S, Pagès JM. Ethidium bromide efflux by *Salmonella*: modulation by metabolic energy, pH, ions and phenothiazines. *Int J Antimicrob Agents.* **2011;** 38: 140-5.

[53] Su CC, Yu EW. Ligand-transporter interaction in the AcrB multidrug efflux pump determined by fluorescence polarization assay. *FEBS Letters.* **2007;** 581: 4972-6.

[54] Martins A, Spengler G, Rodrigues L, Viveiros M, Ramos J, Martins M, Couto I, Fanning S, Pagès JM, Bolla JM, Molnar J, Amaral L. pH Modulation of efflux pump activity of multi-drug resistant Escherichia coli: protection during its passage and eventual colonization of the colon. *PLoS One.* **2009;** 4: e6656.

[55] Bate AB, Kalin JH, Fooksman EM, Amorose EL, Price CM, Williams HM, Rodig MJ, Mitchell MO, Cho SH, Wang Y, Franzblau SG. Synthesis and antitubercular activity of quaternized promazine and promethazine derivatives. *Bioorg Med Chem Lett.* **2007;** 17: 1346-8.

[56] Motohashi N, Sakagami H, Kurihara T, Csuri K, Molnár J. Antiplasmid activity of phenothiazines, benzo[a]phenothiazines and benz[c]acridines. *Anticancer Res.* **1992;** 12: 135-9.

[57] Csiszar K, Molnár J. Mechanism of action of tricyclic drugs on Escherichia coli and Yersinia enterocolitica plasmid maintenance and replication. *Anticancer Res.* **1992;** 12: 2267-72.

[58] Kaatz GW, Seo SM. Inducible *NorA*-mediated multidrug resistance in *Staphylococcus aureus*. *Antimicrob Agents Chemother.* **1995;** 39: 2650-5.

[59] Molnár A, Amaral L, Molnár J. Antiplasmid effect of promethazine in mixed bacterial cultures. *Int J Antimicrob Agents.* **2003;** 22: 217-22.

[60] Spengler G, Molnár A, Schelz Z, Amaral L, Sharples D, Molnar J. The mechanism of plasmid curing in bacteria. *Current Drug Targets.* **2006,** 7: 823-41.

[61] Amaral L, Lorian V. Effects of chlorpromazine on the cell envelope proteins of Escherichia coli. *Antimicrob Agents Chemother.* **1991;** 35: 1923-4.

[62] Amaral L, Kristiansen JE, Frolund Thomsen V, Markovich B. The effects of chlorpromazine on the outer cell wall of *Salmonella* typhimurium in ensuring resistance to the drug. *Int J Antimicrob Agents.* **2000;** 14: 225-9.

[63] Schelz Z, Martins M, Martins A, Viveiros M, Molnar J, Amaral L. Elimination of plasmids by SILA compounds

that inhibit efflux pumps of bacteria and cancer cells. *In Vivo.* **2007;** 21: 635-9.

[64] Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A. Plasmid-mediated quinolone resistance: a multifaceted threat. *Clin Microbiol Rev.* **2009;** 22: 664-89.

[65] Peubez I, Chaudet N, Mignon C, Hild G, Husson S, Courtois V, De Luca K, Speck D, Sodoyer R. Antibiotic-free selection in E. coli: new considerations for optimal design and improved production. *Microb Cell Fact.* **2010;** 9: 65.

[66] Dasgupta A, Mukherjee S, Chaki S, Dastidar SG, Hendricks O, Christensen JB, Kristiansen JE, Amaral L. Thioridazine protects the mouse from a virulent infection by *Salmonella enterica* serovar Typhimurium 74. *Int J Antimicrob Agents.* **2010;** 35: 174-6.

[67] Dastidar SG, Debnath S, Mazumdar K, Ganguly K, Chakrabarty AN. Triflupromazine: a microbicide non-antibiotic compound. *Acta Microbiol Immunol Hung.* **2004;** 51: 75-83.

[68] Gunn JS. The *Salmonella PmrA*B regulon: lipopolysaccharide modifications, antimicrobial peptide resistance and more. *Trends Microbiol.* **2008;** 16: 284-90.

[69] Lemieux B, Percival MD, Falgueyret JP. Quantitation of the lysosomotropic character of cationic amphiphilic drugs using the fluorescent basic amine Red DND-99. *Anal Biochem.* **2004;** 32 : 247-51.

[70] Ishizaki J, Yokogawa K, Hirano M, Nakashima E, Sai Y, Ohkuma S, Ohshima T, Ichimura F. Contribution of lysosomes to the subcellular distribution of basic drugs in the rat liver. *Pharm Res.* **1996;** 13: 902-6.

[71] Ordway D, Viveiros M, Leandro C, Jorge Arroz M, Molnar J, Kristiansen JE, Amaral L. Chlorpromazine has intracellular killing activity against phagocytosed *Staphylococcus aureus* at clinical concentrations. *J Infect Chemother.* **2002;** 8: 227-31.

[72] Clausen T, Harving H, Dahl-Hansen AB. The relationship between the transport of glucose and cations across cell membranes in isolated tissues. *Biochim Biophys Acta.* **1973;** 298: 393-411.

[73] Hansen Kristiansen JE. Fatal chloroquine poisoning with severe hypokalemia. *Ugeskr Laeger.* **1977;** 13: 1666-7.

[74] Kristiansen JEH. Experiments to illustrate the effect of chlorpropmazine on the permeability of the bacterial cell wall. *Acta Pathol Microbiol Scand B.* **1979;** 87: 317-9.

[75] Kristiansen JEH. Are chlorpromazine and other phenothiazines also chemotherapeutics? *Ugeskr Laeger.* **1981;** 143: 1900-4.

[76] Kristiansen JE. The antimicrobial activity of psychotherapeutic drugs and stereo-isomeric analogues. *Dan Med Bull.* **1990;** 37: 165-82.

[77] Kristiansen JE, Hendricks O, Delvin T, Butterworth TS, Aagaard L, Christensen JB, Flores VC, Keyzer H. Reversal of resistance in microorganisms by help of non-antibiotics. *J Antimicrob Chemother.* **2007;** 59: 1271-9.

[78] Mortensen I, Kristiansen JE. The antimicrobial activity of the psychopharmacological agent clopenthixol and its two main metabolites. *Acta Pathol Microbiol Immunol Scand B.* **1987;** 95: 355-9.

[79] Kristiansen JE, Sebbesen O, Frimodt-Møller N, Aaes-Jørgensen T, Hvidberg EF. Synergy between a non-neuroleptic thioxanthene stereo-isomer and penicilline in vivo. *APMIS.* **1988;** 96: 1079-84.

[80] Petersen PV, Lassen N, Holm T, Kopf R, Nielsen IM.

Chemische konstitution und pharmakologische wirkung einiger thiaxanthen-analoge zu chlorpromazine, promazine, und mepazin. *Arzneimittel Forschung.* **1958;** 8: 395-7.

[81] Petersen PV, Nielsen IM, Pedersen V, Jorgensen A, Lassen N. Thioxanthenes. In: Usdin E, Forrest I, eds. *Psychotherapeutic Drugs.* New York: Marcel Dekker, **1977;** 827-67.

[82] Feinberg AP, Snyder SH. Phenothiazine drugs: structure-activity relationships explained by a conformation that mimics dopamine. *Proc Natl Acad Sci USA.* **1975;** 72: 1899-903.

[83] Hendricks O, Christensen JB, Kristiansen JE. Antibakterielle eigenschaften der Phenothiazine. Eine Behandlungsoption für die Zukunft? *Chemotherapie J.* **2004;** 13: 203-5.

[84] Svendsen CN, Froimowitz M, Hrbek C, Campbell A, Kula N, Baldessarini RJ, Cohen BM, Babb S, Teicher MH, Bird ED. Receptor affinity, neurochemistry and behavioral characteristics of the enantiomers of thioridazine: Evidence for different stereoselectivities at D1 and D2 receptors in rat brain. *Neuropharmacology.* **1988;** 27: 1117-24.

[85] Abbate E, Vescovo M, Natiello M *et al.* Tuberculosis extensamente resistenter (XDR-TB) en Argentina: Aspectos destacables epidemiologicos, bacteriologicos, terapeuticos y evolutivos. *Revista Argentina de Medicina Respiratoria.* **2007;** 7: 19-25.

[86] Kristiansen JE, Mortensen I, Gaarslev K. The antibiotic effect of the antidepressive drug femoxetine and its stereo-isomeric analogs on diarrhoea-producing enterobacteriacae. *Acta Pathol Microbiol Immunol Scand B.* **1986;** 94: 103-6.

[87] Bohnert JA, Szymaniak M, Schuster S, Kern WV. Efflux inhibition by selective serotonin reuptake inhibitors in Escherichia coli. *J Antimicrob Chemother.* **2011;** 66: 2057-60.

[88] Lass-Flörl C, Dierich MP, Fuchs D, Semenitz E, Jenewein I, Ledochowski M. Antifungal properties of selected serotonin reuptake inhibitors against Aspergillus species *in vitro*. *J Antimicrob Chemother.* **2001;** 48: 775-9.

[89] Kaatz GW, Moudgal VV, Seo SM, Hansen JB, Kristiansen JE. Phenylpiperidine selective serotonin reuptake inhibitors interfere with multidrug efflux pump activity in *Staphylococcus aureus*. *Int J Antimicrob Agents.* **2003;** 22: 254-61.

[90] Lieb J. The immunostimulating and antimicrobial properties of lithium and antidepressants. *J Infect.* **2004;** 49: 88-93.

[91] Doyle PS, Weinbach EC. The activity of tricyclic antidepressant drugs against Trypanosoma cruzi. *Exp Parasitol.* **1989;** 68: 230-4.

[92] Munoz-Bellido JL, Munoz-Criado S, Garcia-Rodriguez JA. Antimicrobial activity of psychotropic drugs. Selective serotonin reuptake inhibitors. *Int J Antimicrob Agents.* **2000;** 14: 177-80.

[93] Cecchelli C, Grassi G, Pallanti S. Ariprazolev improves depressive symptoms and immunological response to antiretroviral therapy in an HIV-infected subject with resistant depression. *Case Report Med.* **2010;** 2010: 836214.

[94] Abbate E, Vescovo M, Natiello M, Cufré M, García A, Gonzalez Montaner P, Ambroggi M, Ritacco V, van Soolingen D. Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine. *J Antimicrob Chemother.* **2012;** 67: 473-477.

[95] Ordway D, Viveiros M, Leandro C, Jorge Arroz M, Molnar J, Kristiansen JE, Amaral L. Chlorpromazine has intracellular killing activity against phagocytosed *Staphylococcus aureus* at clinical concentrations. *J Infect Chemother.* **2002;** 8: 227-31.

[96] Yakubu MA, Majumder S, Kierszenbaum F. Changes in Trypanosoma cruzi infectivity by treatments that affect calcium ion levels. *Mol Biochem Parasitol.* **1994;** 66: 119-25.

[97] Parveen S, Khan MO, Austin SE, Croft SL, Yardley V, Rock P, Douglas KT. Antitrypanosomal, antileishmanial, and antimalarial activities of quaternary arylalkylammonium 2-amino-4-chlorophenyl phenyl sulfides, a new class of trypanothione reductase inhibitor, and of N-acyl derivatives of 2-amino-4-chlorophenyl phenyl sulfide. *J Med Chem.* **2005;** 48: 8087-97.

[98] Koka S, Lang C, Boini KM, Bobbala D, Huber SM, Lang F. Influence of chlorpromazine on eryptosis, parasitemia and survival of Plasmodium berghei infected mice. *Cell Physiol Biochem.* **2008;** 22: 261-8.

[99] Egan TJ. Turning a chloroquine-resistance reverser into an antimalarial. *Trends Parasitol.* **2002;** 18: 344.

[100] Singh N, Puri SK. Interaction between chloroquine and diverse pharmacological agents in chloroquine resistant Plasmodium yoelii nigeriensis. *Acta Trop.* **2000;** 77: 185-193.